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Abstract 11 
Eudragit® E PO (EPO) is a terpolymer based on N,N-dimethylaminoethyl methacrylate with 12 
methylmethacrylate and butylmethacrylate, produced by Evonik Industries AG as a 13 
pharmaceutical excipient. In this work, EPO was chemically modified through reaction with 14 
acryloyl chloride. The successful modification of EPO was confirmed by FTIR, NMR-15 
spectroscopy, elemental and thermal analysis. The degree of acrylation was determined by 16 
permanganatometric titration. The slug mucosal irritation test was used to demonstrate non-17 
irritant nature of EPO and its acrylated derivatives (AEPO). The mucoadhesive properties of 18 
EPO and AEPO were evaluated using freshly excised sheep nasal mucosa and it was 19 
demonstrated that acrylated polymers facilitated greater retention of sodium fluorescein on 20 
mucosal surfaces compared to solution mixture of this dye solution with EPO as well as free 21 
dye. 22 
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 28 
1. Introduction 29 
Drug delivery through mucosal routes of administration offers numerous advantages 30 
such as improved bioavailability of active pharmaceutical ingredients, ease of therapy 31 
application and in some cases the possibility of targeting particular organs (Andrews et al, 32 
2009; Khutoryanskiy, 2011; Khutoryanskiy, 2014). In recent years, nasal administration has 33 
gained a lot of interest due to the possibility for bypassing the blood-brain barrier and targeting 34 
the brain directly through drug absorption via olfactory mucosa (Gänger et al, 2018; Pires et 35 
al, 2018; Battaglia et al, 2018; Sonvico et al, 2018). This minimally invasive route to deliver 36 
drugs directly to the brain could potentially offer new opportunities for treating various 37 
neurodegenerative disorders such as Alzheimer’s, Parkinson’s and Huntington’s diseases 38 
(Poovaiah et al, 2018).  39 
Nasal cavity is an organ of human respiration, evolved to serve several functions, 40 
including air conditioning and protection from various pathogenic microorganisms. The 41 
protective function of the nasal cavity is achieved through mucociliary clearance, a 42 
physiological mechanism that helps to trap dust and microorganisms present in the air within 43 
the mucus blanket that is continuously produced and eventually moved into the digestive 44 
system. This dynamic and sticky nature of the mucus layer ensures the prevention of potential 45 
entry of microorganisms to the lungs (Washington et al, 2000; Hillery et al, 2001). 46 
The mucus layer in the nasal cavity could act as a barrier that hampers the diffusion of 47 
drugs to reach epithelial cells, which may reduce the efficiency of therapeutic agents 48 
administered via intranasal route. One potential approach to improve the efficiency of drugs 49 
administered via intranasal route is the use of mucoadhesive dosage forms, capable to ensure 50 
longer residence in the nasal cavity (Ugwoke et al, 2005).  51 
Cationic polymers are known to have excellent mucoadhesive properties due to their 52 
ability to interact with negatively charged mucins via electrostatic attraction forces. Examples 53 
of cationic polymers with proven mucoadhesive properties include chitosan (Sogias et al, 2008) 54 
and some synthetic polymers of methacrylate nature with tertiary-amino- and quaternary 55 
ammonium- functional groups (Keely et al, 2005; Fefelova et al, 2007). Some attempts were 56 
reported to improve mucoadhesive properties of chitosan and other polymers through their 57 
chemical functionalisation, for example, attachment of thiol- (Bernkop-Schnurch, 2004; 58 
Bernkop-Schnurch, 2005), acrylate- (Davidovich-Pinhas et al, 2011; Shitrit et al, 2017), 59 
methacrylate- (Kolawole et al, 2018), catechol- (Kim et al, 2015),  maleimide- (Tonglairoum 60 
et al, 2016; Shtenberg et al, 2017; Sahatsapan et al, 2018) and other groups (Ways et al, 2018).  61 
Recently, we have reported the synthesis of mucoadhesive nanogels by polymerisation 62 
of 2-dimethylamino)ethyl methacrylate in the presence of N,N’-methylene-bis-acrylamide as a 63 
crosslinking agent (Brannigan et al, 2017). The resulting nanogels were subsequently modified 64 
by the reaction with acryloyl chloride to introduce acrylated groups capable of forming 65 
covalent linkages with thiols present in mucins under physiological conditions. These acrylated 66 
nanogels exhibited superior mucoadhesive properties compared to the original poly((2-67 
dimethylamino)ethyl methacrylate) nanogels, when tested using bovine ocular mucosa.  68 
Eudragit® E PO (EPO) is a linear cationic polymer manufactured and marketed by 69 
Evonik Industries AG as a pharmaceutical excipient. EPO is a terpolymer that is composed of 70 
N,N-dimethylaminoethyl methacrylate (DMAEMA), methylmethacrylate and 71 
butylmethacrylate. The combination of these repeating units within this polymer ensures its 72 
solubility in water only under acidic conditions (insoluble in the mouth), which is applicable 73 
in the design of dosage forms with taste and odour masking. Once EPO coated dosage form 74 
moves into the stomach the acidity of the gastric juice will ensure its quick dissolution and drug 75 
release (Evonik technical notes, 2018). The ability of cationic EPO to form interpolyelectrolyte 76 
complexes with various anionic polymers was also previously used in the design of solid 77 
dosage forms for gastrointestinal delivery (Mustafin, 2011; Mustafin et al, 2011). Since EPO 78 
is an approved pharmaceutical excipient and it does contain DMAEMA units in the terpolymer 79 
structure, it opens up an interesting opportunity for its simple chemical modification using the 80 
chemistry previously described by Brannigan and Khutoryanskiy (2017) with the aim to 81 
prepare materials with enhanced mucoadhesive properties.  82 
 In the present study, we have modified EPO chemically through its reaction with 83 
acryloyl chloride, which resulted in formation of acrylated polymers. The resulting products 84 
were characterised using 1H NMR and FTIR spectroscopy, thermal analysis, 85 
permanganatometric titration and elemental analysis. The biocompatibility of parent EPO and 86 
its acrylated derivatives were studied using slug mucosal irritation test. Liquid formulations 87 
were prepared using EPO and its acrylated derivatives with sodium fluorescein as a model 88 
compound and their retention on freshly excised sheep nasal mucosa was evaluated using 89 
fluorescent microscopy.  90 
 91 
2. Experimental part 92 
2.1. Materials 93 
Eudragit® E PO (EPO) with weight-average molecular weight 135,000 was received as a gift 94 
from Evonik Röhm GmbH (Darmstadt, Germany). Acryloyl chloride was purchased from Alfa 95 
Aesar (Lancashire, United Kingdom). Tetrahydrofuran anhydrous, deuterated chloroform 96 
(CDCl3), calcium chloride dehydrate, sodium chloride, potassium chloride, sodium fluorescein 97 
were obtained from Sigma-Aldrich (Gillingham, United Kingdom). Sulfuric acid, potassium 98 
permanganate and oxalic acid were received as a chemical standard from Uralhiminvest (UFA, 99 
Russia). Dialysis membranes (Mw cut-off = 12-14 kDa) were purchased from Medicell 100 
International Ltd (London, United Kingdom). Ultrapure water (Millipore, Bedford, MA, 101 
U.S.A) was used for all aqueous solutions and all other chemicals were used as supplied 102 
without modification. 103 
 104 
2.2. Methods 105 
2.2.1. Synthesis of acrylated EPO 106 
Acrylated EPO was synthesized in a clean dry round-bottom flask with magnetic stirring. 107 
Briefly, 2 g of EPO was dissolved in 100 mL tetrahydrofuran with permanent stirring at room 108 
temperature. Acryloyl chloride was added dropwise to the resulting solutions with vigorous 109 
stirring during 20 min at room temperature. In order to achieve 50 % and 25 % of acryloylation 110 
2.88 mL and 1.44 mL of acryloyl chloride were used and the resulting samples are referred as 111 
AEPO50 and AEPO25, respectively. The reaction mixtures were left for 72 hours at room 112 
temperature with gentle stirring. The reaction mixtures were then transferred to a dialysis 113 
membrane and dialyzed against deionised H2O (5L deionised H2O for 3 days changing the 114 
dialysis media three times a day). The resulting products were freeze-dried using Heto Power 115 
Dry LL 3000 freeze-drier (Thermo Electron Corporation). 116 
 117 
2.2.2. Preparation of artificial nasal fluid  118 
Artificial nasal fluid (ANF) was prepared according to the protocol described by Barbi et al.  119 
(2014) with minor changes. Solution was prepared by dissolving 7.45 g NaCl, 1.29 g KCl and 120 
0.32 g CaCl22H2O in 1000 mL deionised water. The solution was left stirring overnight at 121 
room temperature. The artificial nasal fluid was kept at 37 °C in a water bath throughout the 122 
experiments.  123 
2.2.3. Fourier transform infrared spectroscopy (ATR-FTIR) 124 
The ATR-FTIR spectra of EPO, AEPO25 and AEPO50 powders were recorded using a Nicolet 125 
iS5 FTIR spectrometer (Thermo Scientific, U.S.A.) equipped with a DTGS detector. The 126 
samples were directly mounted over the iD5 smart single bounce ZnSe ATR crystal and 127 
scanned from 4000 to 400 cm−1. OMNIC spectra software was used for the analysis of results. 128 
Origin®software (Scientific Graphing & Analysis software, Version 7.5, OriginLab Corp., 129 
USA) was used for plotting graphs. 130 
 131 
2.2.4.1H nuclear magnetic resonance spectroscopy (1H NMR) 132 
1H nuclear magnetic resonance spectra were recorded for EPO, AEPO25 and AEPO50 using a 133 
DPX 400 MHz NMR spectrometer (Bruker, Germany). All samples were dissolved in 134 
deuterated chloroform and transferred to 5 mm Norell tubes (Standard Series™ 400 MHz 135 
NMR). All chemical shifts were reported as δ in parts per million (ppm). 136 
2.2.5. Elemental analysis 137 
Elemental analysis was performed using Thermo Flash 2000 CHNS/O elemental analyzer 138 
(Thermo Fisher Scientific, Paisley, UK). The vacuum dried samples (at 40 ºC for 2 days) were 139 
weighed into a crucible on a micro balance (Mettler Toledo XP6 Excellence Plus XP Micro 140 
Balance, Switzerland). The crucibles with samples were packed and placed into the combustion 141 
reactor via autosampler. Temperature in the oven was 900 ºC, and a gas flow rate was 10 142 
mL/min.  Calibration of the instrument was performed with atropine standard (Thermo Fisher 143 
Scientific, Paisley, UK). Eager Xperience Data Handling Software was used to analyze the 144 
results. 145 
 146 
2.2.6. Thermal analysis  147 
Modulated differential scanning calorimetry (mDSC) experiments were carried out using a 148 
Discovery DSC™ (TA Instruments, New Castle, DE, U.S.A.), equipped with a refrigerated 149 
cooling system (RCS90). These experiments were performed under dry nitrogen atmosphere 150 
at 50 mL/min flow rate. Tzero® aluminum pans (TA Instruments, New Castle, DE, U.S.A.) 151 
were used in mDSC experiments. Indium and n-octadecane were used as standards to calibrate 152 
the DSC temperature scale. The modulation parameters used were: 2 °C/min heating rate, 40 s 153 
period and 0.212 °C amplitude.  154 
Thermogravimetric analysis (TGA) was performed using Discovery TGA™ (TA Instruments, 155 
New Castle, DE, U.S.A.). Samples (10-15 mg) heated in aluminum pans from 25 to 500 °C at 156 
10 °C/min.  157 
mDSC and TGA results were analysed using TRIOS™ software, version 3.1.5.3696 (TA 158 
Instruments, New Castle, DE, U.S.A.). 159 
2.2.7. Back permanganometric titration 160 
Briefly, 30 mL of 0.2 N H2SO4 were placed in a conical flask with a Quickfit glass stopper. 161 
Approximately, 50-100 mg of acrylated polymer were then added to H2SO4 and left stirring 162 
until complete polymer dissolution. To this solution 10 mL of 0.1 N potassium permanganate 163 
was added, followed with 4 mL of 0.1 N oxalic acid added from a microburette. These solutions 164 
then were stirred and heated to 60 °C. This resulted in a change of solution colour from purple 165 
to brown. The presence of small quantities of oxalic acid resulted in reduction of some MnO4
- 166 
ions to Mn2+, which act as a catalyst and speed up the reaction of permanganate ions with oxalic 167 
acid added subsequently. The reaction mixtures were then slowly titrated with 0.1 N oxalic 168 
acid (4 drops per minute). Each titration was repeated in 5 times and the mean values were 169 
calculated. 170 
The degree of EPO acrylation was determined according to the formula: 171 
𝑋 =
(𝑉1−𝑉2)∗𝐾∗𝑇100 %
𝑎
, 172 
where  173 
𝑉1–volume of oxalic acid, consumed in the control experiment, mL 174 
𝑉2–volume of oxalic acid, consumed in the experiment, mL 175 
𝐾–correction factor (K=1.0000), 176 
𝑇–a titre of oxalic acid to acrylated polymer (T=1.2714 mg/mL). 177 
𝑎–polymer sample weight, mg  178 
  179 
2.2.8. Slug mucosal irritation test 180 
Limax flavus slugs weighing 3-8 g were sourced locally in Harris Garden (Reading, UK). The 181 
slug mucosal irritation test was conducted using slightly modified procedure reported by 182 
Khutoryanskaya et al (2008). Solutions for slug mucosal irritation test were prepared by 183 
dissolving 20 mg of EPO, AEPO25 and AEPO50 in 20 mL deionised water with pH adjusted 184 
to 5.7 with 1 M NaOH or 1 M CH3COOH solutions. Benzalkonium chloride (10 mg) was 185 
dissolved in 100 mL deionized water and adjusted to pH=5.7 with 1 M NaOH to be used as a 186 
positive control. Each slug was kept in 0.5-1 L glass beakers with a tissue paper moistened 187 
with 20 mL ANF solution and left for two days at room temperature prior to experiments. Then 188 
each slug was washed with 2 mL of ANF solution, excess of moisture on their body was 189 
carefully removed with a tissue paper, and then they were put on Petri dishes with Whatman 190 
filter paper moistened with 2 mL sample solutions. The samples included positive control (1 191 
% benzalkonium chloride), negative control (ANF), as well as 1 mg/mL solutions of EPO, 192 
AEPO25 and AEPO50. Slugs were kept in contact with the studied samples for1 h, then they 193 
were taken out, washed with 10 mL of ANF and carefully wiped with a tissue paper. All slugs 194 
were then individually weighed before and after experiment using analytical balance. The 195 
mucus production (MP) was determined as a slug body weight loss and calculated according 196 
to the formula: 197 
MP = (mb-ma) ⁄mb100 %, 198 
where ma and mb are the weights of a slug after and before each experiment, respectively.  199 
All experiments were conducted using different slugs (n=5).  200 
 201 
2.2.9. Retention studies 202 
Experiments on retention of polymer formulations on nasal mucosal surfaces were conducted 203 
using the fluorescent techniques developed and described by the Khutoryanskiy group earlier 204 
(Irmukhametova et al, 2011; Štorha et al, 2013; Mun et al, 2016; Kaldybekov et al, 2018; 205 
Ways et al, 2018). Sodium fluorescein solutions (0.001 mg/mL) were prepared in deionised 206 
water and used as a medium for dissolving polymer samples. Then, 10 mg of EPO, AEPO25 207 
or AEPO50 were dispersed in10 mL of sodium fluorescein solutions and pH of these mixtures 208 
was adjusted to pH=5.7. These dispersions were left for 24 h at room temperature with stirring 209 
until complete dissolution and were protected from light by aluminium foil. 210 
Sheep mucosal tissues are commonly used in the ex vivo studies on nasal drug delivery (Gavini 211 
et al, 2008; Pund et al, 2013). Sheep heads were obtained from the local abattoir (Kazan, 212 
Russia) and transported to the laboratory in a cold box (3-4 °C). The nasal septum tissue 213 
containing mucosal lining (1.53 cm) was carefully dissected and extracted from each head 214 
with scissors; it was washed with 1 mL of ANF and placed on a microscopy slide. All tissues 215 
were used within 24 h after animal slaughter and each experiment was conducted in triplicate. 216 
All experiments with retention of formulations on nasal mucosa were conducted at 37 °C in a 217 
thermostat. Images of mucosal surfaces were taken using fluorescent microscope (Olympus 218 
BX63), equipped with Alexa-488 filter. All images were of 4 magnification and were taken 219 
at 512 ms exposure time and 1376-1038 pixels. Initially, fluorescence images of mucosal 220 
tissues were recorded for each sample as a background fluorescence intensity. Then, 50 μL 221 
solutions of 1 mg/mL EPO, AEPO25, AEPO50 containing 0.001 mg/mL sodium fluorescein 222 
were placed on mucosal surface and fluorescence images were recorded again. The mucosal 223 
tissues were then transferred to a thermostat and irrigated with ANF using a syringe pump (0.43 224 
mL/min). Fluorescence images of these mucosal tissues were taken at different time points. 225 
ImageJ software was used for analysis of the resulting microscopy images by measuring the 226 
pixel intensity after each wash. Results were presented as fluorescence intensity values versus 227 
the volume of ANF. Background images were used to normalize the mean values by subtracting 228 
the background fluorescence after each wash. The experiments were conducted in triplicate. 229 
Solution of sodium fluorescein in deionised water (0.001 mg/mL) was used as a negative 230 
control. 231 
 232 
2.2.10. Statistical analysis 233 
GraphPad Prism statistical analysis software (version 5.0) was used to analyze data acquired 234 
during these experiments using one-way analysis of variance ANOVA and paired t-tests.  235 
Results were presented as the mean ± standard deviation and probability of p < 0.05 was 236 
considered as significant. All measurements were reported in triplicate, unless otherwise 237 
specified. 238 
 239 
Results and Discussion 240 
Synthesis of acrylated EPO 241 
Previously, Brannigan and Khutoryanskiy (2017) have demonstrated that poly((2-242 
dimethylamino)ethyl methacrylate nanogels modified by reaction with acryloyl chloride 243 
exhibited greater retention on ocular mucosa compared to unmodified polymers. Similar 244 
modification is also possible for Eudragit® EPO, Eudragit® RL and Eudragit® S100 copolymers 245 
containing 25 %, 10 % and 5 % of dimethylamino-groups, respectively (Mustafin, 2011; 246 
Moustafine et al, 2011; Moustafine et al, 2013). To demonstrate this possibility Eudragit® EPO 247 
was chosen for chemical modification using acryloylation according to the reaction scheme 248 
shown in Figure 1.Two batches of acrylated EPO with 25 % and 50 % substitution of the 249 
dimethylamino groups were synthesised (AEPO25 and AEPO50, respectively). (Figure 1 is 250 
here). 251 
 252 
Characterisation of polymers using spectroscopic and thermal methods 253 
The successful modification of EPO was confirmed by FTIR-spectroscopy (Figure 2). The 254 
FTIR-spectra of EPO, AEPO25 and AEPO50 show the characteristic bands for non-ionised 255 
dimethylamino groups between 2770-2824 cm−1 (Moustafine et al, 2011), whose intensity 256 
becomes weaker with acryloylation. However, the spectra of AEPO25 and AEPO50 also show 257 
the presence of a new band at 1605 cm–1 indicating the attachment of additional carbonyl 258 
groups to EPO. Moreover, the FTIR spectra of AEPO25 and AEPO50 demonstrate the bands 259 
at 960-966 cm−1 and 989 cm−1 corresponding to quaternary ammonium groups (Moustafine et 260 
al, 2012), which change depending on the degree of acryloylation.  261 
(Figure 2 is here) 262 
Additionally, we also used 1H-NMR to confirm the chemical structure of modified polymers 263 
(Figure 3). The spectra of AEPO25 and AEPO50 show the appearance of a new multiplet 264 
between 5.98–6.44 ppm, which confirmed the presence of acryloyl groups. The intensity of 265 
these peaks decreases due to the reduction in the degree of substitution of dimethylamino 266 
groups. The appearance of a 5.98–6.44 ppm multiplet in the spectra of AEPO is generally 267 
consistent with NMR characterisation of acrylated PDMAEMA previously reported by 268 
Brannigan and Khutoryanskiy (2017), who used this method to determine the degree of 269 
acryloylation. However, unfortunately, the complex mixture of signals resulting from different 270 
repeating units of EPO leads to an overlap of many peaks; this made impossible to use 1H-271 
NMR spectroscopy for quantitative determination of the degrees of acryloylation.  272 
(Figure 3 is here) 273 
Conjugation of acryloyl groups to EPO potentially should lead to some reduction in nitrogen 274 
content in the samples, which could be studied using elemental analysis. According to Table 275 
1, nitrogen content in EPO is 4.30±0.12wt %. AEPO25 and AEPO50 showed 3.60±0.20wt % 276 
and 3.79±0.24wt % of nitrogen, respectively. This was a statistically significant reduction in 277 
nitrogen content compared to unmodified EPO (p<0.05); however, there was no significant 278 
difference between AEPO25 and AEPO50 (p>0.05). The lack of statistically significant 279 
difference between AEPO25 and AEPO50 does not allow the calculation of the degree of 280 
acryloylation based on elemental analysis data.  281 
In the next step, the influence of the new acryloyl groups on the thermal behavior of EPO was 282 
investigated.  mDSC results demonstrate the presence of single glass transition events both in 283 
EPO and AEPO samples (Figure 4). The parent EPO displayed the presence of a Tg at 49.5 284 
C, which is consistent with the previous reports (Moustafine et al, 2006; Menjoge and 285 
Kulkarni, 2007; Claeys et al, 2013). A reduction of dimethyl amino groups content and their 286 
partial replacement with quaternized nitrogen and acryloyl group resulted in copolymers with 287 
substantial increase in glass transition temperatures: Tg of EPO increased from 49.5 °C to 94.5 288 
°C and 81.9 °C for AEPO25 and AEPO50, respectively. The changes in Tg values of modified 289 
polymers compared to parent material qualitatively indicate the successful derivatization of 290 
EPO.  Similar effects with increase in the Tg values upon reduction in the number of dimethyl 291 
amino groups content in a terpolymer structure were previously reported by Claeys et al (2013). 292 
A slightly unexpectedly lower Tg value of AEPO50 (81.9 °C) compared to AEPO25 (94.5 °C) 293 
could potentially be related to the effects of quaternization, similarly to quaternized polymers 294 
- Eudragit® RL and RS types, which are characterized by low Tgs (Eudragit® Application 295 
Guidelines, 2012).  296 
(Figure 4 is here). 297 
TGA thermogram of parent EPO (Figure 5) showed the first weight loss event at 271.6–316.8 298 
°C (29.6 %) possibly related to the removal of dimethylamino groups and formation of six-299 
membered cyclic anhydrides as proposed by Lin et al (1999). The second weight loss at 350.0-300 
475.0 °C (68.9 %) corresponds to a further complete decomposition of the terpolymer. The 301 
acrylated derivatives of EPO show distinctly different thermal decomposition profiles 302 
consisting of three degradation stages. In the case with AEPO, the first decomposition event 303 
begins at around 40 oC and finishes at 200 C resulting in a weight loss of 3.9 % and 4.0 % for 304 
AEPO25 and AEPO50, respectively. This is likely related to the dehydration of a sample and 305 
removal of some moisture. It is interesting to note that moisture content in the parent EPO was 306 
practically not detectible, which may indicate that AEPO samples are more hydrophilic and 307 
hygroscopic compared to EPO. The second decomposition stage in AEPO25 is observed at 308 
200.0-337.5 °C (31.9 %), followed by the third weight loss at 337.5-475.0 °C (60.0 %). 309 
AEPO50 displayed the second and third decomposition events at 200.0-337.5 °C (28.7 %) and 310 
337.5-475.0 °C (62.6 %), respectively. Overall, the second degradation event of acrylated EPO 311 
samples starts at 50-60 °C earlier compared to the first weight loss of parent EPO, but the final 312 
decomposition stages of the synthesized samples occurred in the similar range (at 400-450 °C). 313 
A decrease in the thermal stability of modified EPO is possibly related to the presence of 314 
acryloyl groups, which are more chemically reactive and may undergo degradation at lower 315 
temperatures. 316 
 317 
(Figure 5 is here)  318 
 319 
Determination of the degrees of acryloylation 320 
Since it was not possible to determine the degrees of acryloylation of EPO using 1H NMR (due 321 
to the overlap of some characteristic signals in the spectrum) permanganatometric titration 322 
technique was used. This was a back-titration method, where an excess of potassium 323 
permanganate solution was used to oxidise unsaturated acryloyl groups in the polymer and 324 
unreacted permanganate was titrated with oxalic acid. Oxalate reacts very slowly with 325 
permanganate ions at room temperature, thus the solutions were titrated approximately at 60 326 
C to make this procedure more practical. In agreement with the manufacturer’s specifications 327 
(Eudragit® Application Guidelines, 2013) EPO contains 22.6 % of quaternary amino groups. 328 
According to this data, the modified polymers (AEPO25 and AEPO50) should have 5.65 % 329 
and 11.30 % of acryloyl groups, respectively, which was confirmed by permanganatometry 330 
(Table 1).  331 
(Table 1 is here). 332 
Toxicological Investigation 333 
In order to evaluate toxicological properties of modified polymers slug mucosal irritation test 334 
was performed. This test was established and validated as a reliable method for preliminary 335 
evaluation of irritation potential of chemicals to various mucosal membranes, including studies 336 
of nasal irritation (Adriaens et al, 2001; Adriaens and Remon, 2002; Lenoir et al, 2011; Lenoir 337 
et al, 2013). In this test, the first sign of good biocompatibility is colorless mucus, secreted by 338 
slugs. Second, the amount of mucus production, which increased in stronger irritating 339 
conditions (Khutoryanskaya et al, 2008; Adriaens et al, 1999; Adriaens and Remon, 2002). In 340 
a positive control experiment (1% benzalkonium chloride) slugs suffered a severe irritation, 341 
with 28.02±2.70 % production of yellow mucus (Figure 6), which is consistent with the 342 
previous reports (Khutoryanskaya et al, 2008). The slugs exposed to solutions with EPO 343 
produce 4.55±2.26 % colorless mucus, confirming non-irritating nature of this polymer. The 344 
mucus production values recorded for AEPO25 and AEPO50 were 3.38±1.37 and in 4.40±2.29 345 
%, respectively. No significant difference was observed between mucus production values 346 
recorded for negative control, EPO, AEPO25 and AEPO50 (p<0.05), indicating non-irritating 347 
nature of modified EPO.  348 
 349 
(Figure 6 is here). 350 
 351 
Mucoadhesion studies 352 
The retention studies with fluorescent detection of different mucoadhesive formulations on 353 
different surfaces were described in previous publications (Irmukhametova et al, 2011; Storha 354 
et al, 2013; Cook et al, 2015; Mun et al, 2016; Kaldybekov et al, 2018; Ways et al, 2018). This 355 
flow-through test evaluating the retention of formulations on mucosal surfaces usually gives 356 
good correlation with other methods (e.g. tensile studies) used to characterize mucoadhesive 357 
properties (Kolawole et al, 2019). In the present work the retention properties of EPO, 358 
AEPO25, AEPO50 solutions containing sodium fluorescein were studied on freshly excised 359 
sheep nasal mucosa, irrigated with artificial nasal fluid (ANF).  Fluorescent images of these 360 
samples are presented in Figure 7.  361 
(Figure 7 is here). 362 
Figure 8 shows the retention of EPO, AEPO25, AEPO50 solutions containing sodium 363 
fluorescein on sheep nasal mucosa after analysis of the fluorescent images. It was established 364 
that parent EPO exhibits mucoadhesive properties and retains the dye on mucosal surface better 365 
compared to free sodium fluorescein. Approximately, 3.19±1.40 % of fluorescence remained 366 
on nasal mucosa after 60 min washing. This good retention of the dye mediated with EPO on 367 
mucosal surfaces is likely to be related to its cationic nature that ensures electrostatic attraction 368 
of this polymer to negatively charged mucosal surface. AEPO25 and AEPO50 facilitated even 369 
greater retention of the dye on nasal mucosa compared to EPO: their retention after 60 mins of 370 
washing is 6.34±1.01 and 10.89±3.48 %, respectively. This difference is statistically significant 371 
(p<0.05), demonstrating superior mucoadhesive performance of acrylated polymers.  372 
(Figure 8 is here)  373 
Conclusions 374 
This study demonstrated successful chemical modification of Eudragit® E PO through reaction 375 
with acryloyl chloride resulting in acrylated polymers. The structure and physicochemical 376 
properties of these polymers were studied using FTIR and 1H NMR spectroscopies, mDSC and 377 
TGA thermal methods as well as by back permanganatometric titration. The slug mucosal 378 
irritation test was used to demonstrate non-irritant nature of modified polymers. Acrylated 379 
polymers exhibited superior mucoadhesive properties on nasal mucosa tissue compared to 380 
parent Eudragit® E PO. Acrylated EPO can potentially be used as a mucoadhesive material for 381 
formulation of dosage forms for transmucosal drug delivery. To the best of our knowledge, this 382 
is the first study reporting the chemical modification of EPO with the aim to enhance its 383 
mucoadhesive properties.   384 
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  543 
Tables: 544 
 545 
Table 1. Quantitation and physicochemical properties of acrylated EPO 546 
Sample Acryloyl 
chloride 
(mL) 
Content of 
acryloyl 
groupsa(%) 
 
Degree of 
acryloylation 
(%)b 
Nitrogen content 
(%)c 
EPO 0 0 0 4.30±0.12 
 
AEPO25 1.44 5.7±0.4 
 
25.1±1.6 
 
3.60±0.20 
 
AEPO50 2.88 11.3±0.2 
 
50.0±0.8 
 
 
3.79±0.24 
a,bDetermined by permanganatomethric titration (n=5, p<0.05).c Determined by elemental 547 
analysis.  548 
  549 
Figures: 550 
 551 
Figure 1. Synthesis of acrylated EPO (25 °С, 72 h).  552 
Figure 2. FTIR spectra of EPO, AEPO25 and AEPO50. 553 
 554 
 555 
 556 
 557 
 558 
 559 
 560 
 561 
 562 
 563 
Figure 3. 1H NMR spectra of EPO, AEPO25 and AEPO50 (CDCl3, 400 MHz).  564 
 565 
 566 
Figure 4.  mDSC thermograms of EPO,AEPO25 and AEPO50.   567 
 568 
Figure 5. TGA thermograms of EPO, AEPO25 and AEPO50. 569 
 570 
 571 
 572 
Figure 6. Mucus production by Limax flavus slugs in response to the contact with solutions of 573 
1 wt % benzalkonium chloride (positive control), ANF (negative control), 0.1 wt % EPO, 574 
AEPO25 and AEPO50 (pH=5.7). Data are expressed as mean ± standard deviation (n=5). Inset: 575 
exemplar images of Limax flavus slugs in positive (A) and negative (B) controls experiment. 576 
 577 
Figure 7. Fluorescent images showing retention of 1 mg/mL EPO, AEPO25, AEPO50 578 
solutions with 0.001 mg/mL sodium fluorescein, and pure 0.001 mg/mL sodium fluorescein 579 
solution on sheep nasal mucosa as washed with ANF. Scale bar is 200 µm.  580 
 581 
Figure 8. Retention of 1 mg/mL EPO, AEPO25, AEPO50 solutions with 0.001 mg/mL sodium 582 
fluorescein and pure 0.001 mg/mL sodium fluorescein solution on sheep nasal mucosa as 583 
washed with different volumes of ANF (pH=5.7, n=3, mean ± SD, “*” represents p < 0.05).   584 
 585 
 586 
